A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Xp13512/Gsk1838262 in the Treatment of Patients With Primary Restless Legs Syndrome

Abstract

XP13512 1800 mg/day significantly reduced RLS symptoms, improved sleep, and was generally well tolerated in subjects with moderate-to-severe primary RLS across 14 days of treatment.